Ultragenyx Pharmaceutical (RARE) Cash & Equivalents (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash & Equivalents data on file, last reported at $175.0 million in Q1 2026.

• Quarterly Cash & Equivalents rose 37.8% year-over-year to $175.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $175.0 million (up 37.8% YoY) and the FY2025 annual result came in at $421.0 million, up 141.95% from the prior year.
• Cash & Equivalents slipped to $175.0 million in Q1 2026 per RARE's latest filing, from $421.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $480.7 million in Q2 2024 and bottomed at $72.6 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $159.9 million (2022), against an average of $196.0 million.
• The widest annual swing landed in 2023, when Cash & Equivalents sank 81.47%; it then surged 371.0% in 2024.
• Tracing RARE's Cash & Equivalents over 5 years: stood at $132.9 million in 2022, then soared by 60.97% to $214.0 million in 2023, then fell by 18.69% to $174.0 million in 2024, then jumped by 141.95% to $421.0 million in 2025, then slumped by 58.43% to $175.0 million in 2026.
• Per Business Quant, the three latest RARE Cash & Equivalents figures stand at $175.0 million (Q1 2026), $421.0 million (Q4 2025), and $202.5 million (Q3 2025).

Peer Comparison